Share General Information
Ponesimod is a small molecule compound that acts as a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P1R), indicated for the treatment of relapsing forms of multiple sclerosis in its finished dose – including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponesimod’s mechanism of action involves modulating the sphingosine 1-phosphate receptor 1 (S1P1R) on lymphocytes. By binding to and stimulating S1P1R, ponesimod initiates the internalization of this receptor on the surface of lymphocytes. This internalization effectively blinds the lymphocytes to concentration gradients of sphingosine 1-phosphate (S1P), which is the natural ligand for S1P1R.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
